BioCentury | Jan 21, 2021
Management Tracks

MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar,  and Imara

...bomedemstat (IMG-7289), a small molecule inhibitor of LSD1 to treat myeloproliferative neoplasms. Plunkett was CFO at Nkarta Inc....
BioCentury | Dec 23, 2020
Finance

NASDAQ IPOs’ class of 2020 far outpaces prior years: Data Byte

...million, while allogeneic NK cell therapy play Nkarta Inc....
BioCentury | Nov 20, 2020
Finance

SR One’s newfound freedom allows firm to increase focus on company creation

...$3.7 billion; and NK cell therapy play Nkarta Inc....
BioCentury | Nov 4, 2020
Politics, Policy & Law

Warp Speed co-leader Slaoui signs letter supporting Fauci

...NASDAQ:FOLD); Paul Hastings, president and CEO of Nkarta...
...company,” according to a disclaimer. Steve Usdin Ovid Therapeutics Inc. Nkarta Inc. Global...
BioCentury | Oct 7, 2020
Management Tracks

CMO Noonberg enters Maze; plus Neogene, Expansion, Nkarta, Supernus and Myriad

...hired Renato Skerlj as president and CEO. Skerlj was most recently CSO of X4 Pharmaceuticals Inc. Nkarta Inc....
...Patrick, who is retiring. Alexander Ford has resigned as COO of Myriad Genetics Inc. (NASDAQ:MYGN). Virginia Li Maze Therapeutics Expansion Therapeutics Nkarta Inc. Supernus...
BioCentury | Sep 3, 2020
Product Development

BIO leaders urge industry to hew to norms for COVID-19 candidates

...Inc. (NASDAQ:OVID); Hastings is president and CEO of Nkarta Inc....
BioCentury | Jul 25, 2020
Finance

Preclinical IPOs attracting big money, but yet to see exponential growth of clinical peers

...year as two additional preclinical IPOs priced deals above $200 million: NK cell therapy play Nkarta Inc....
BioCentury | Jul 24, 2020
Finance

Four more biotech IPOs reach the market, but no big first-day pop in the bunch

...to 10%. That’s well shy of the triple-digit first-day gains for recent listings such as Nkarta Inc....
...Berkeley Lights Inc. (NASDAQ:BLI); many others have posted gains in the high double digits (see “Nkarta’s...
BioCentury | Jul 17, 2020
Finance

Data Bytes: preclinical IPO performance trending up

...was not included in the analysis because the deal priced in July. Cell therapy play Nkarta Inc....
...of the overallotment; the stock is up 105% since the deal priced at $18 (see “Nkarta’s...
BioCentury | Jul 14, 2020
Finance

Three biotechs step up to the IPO plate following Nkarta’s debut

...their offerings or priced above expectations. The most recent example of this trend came from Nkarta Inc....
...and selling more shares than expected, even after upsizing its proposal a day earlier (see “Nkarta’s...
Items per page:
1 - 10 of 28
BioCentury | Jan 21, 2021
Management Tracks

MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar,  and Imara

...bomedemstat (IMG-7289), a small molecule inhibitor of LSD1 to treat myeloproliferative neoplasms. Plunkett was CFO at Nkarta Inc....
BioCentury | Dec 23, 2020
Finance

NASDAQ IPOs’ class of 2020 far outpaces prior years: Data Byte

...million, while allogeneic NK cell therapy play Nkarta Inc....
BioCentury | Nov 20, 2020
Finance

SR One’s newfound freedom allows firm to increase focus on company creation

...$3.7 billion; and NK cell therapy play Nkarta Inc....
BioCentury | Nov 4, 2020
Politics, Policy & Law

Warp Speed co-leader Slaoui signs letter supporting Fauci

...NASDAQ:FOLD); Paul Hastings, president and CEO of Nkarta...
...company,” according to a disclaimer. Steve Usdin Ovid Therapeutics Inc. Nkarta Inc. Global...
BioCentury | Oct 7, 2020
Management Tracks

CMO Noonberg enters Maze; plus Neogene, Expansion, Nkarta, Supernus and Myriad

...hired Renato Skerlj as president and CEO. Skerlj was most recently CSO of X4 Pharmaceuticals Inc. Nkarta Inc....
...Patrick, who is retiring. Alexander Ford has resigned as COO of Myriad Genetics Inc. (NASDAQ:MYGN). Virginia Li Maze Therapeutics Expansion Therapeutics Nkarta Inc. Supernus...
BioCentury | Sep 3, 2020
Product Development

BIO leaders urge industry to hew to norms for COVID-19 candidates

...Inc. (NASDAQ:OVID); Hastings is president and CEO of Nkarta Inc....
BioCentury | Jul 25, 2020
Finance

Preclinical IPOs attracting big money, but yet to see exponential growth of clinical peers

...year as two additional preclinical IPOs priced deals above $200 million: NK cell therapy play Nkarta Inc....
BioCentury | Jul 24, 2020
Finance

Four more biotech IPOs reach the market, but no big first-day pop in the bunch

...to 10%. That’s well shy of the triple-digit first-day gains for recent listings such as Nkarta Inc....
...Berkeley Lights Inc. (NASDAQ:BLI); many others have posted gains in the high double digits (see “Nkarta’s...
BioCentury | Jul 17, 2020
Finance

Data Bytes: preclinical IPO performance trending up

...was not included in the analysis because the deal priced in July. Cell therapy play Nkarta Inc....
...of the overallotment; the stock is up 105% since the deal priced at $18 (see “Nkarta’s...
BioCentury | Jul 14, 2020
Finance

Three biotechs step up to the IPO plate following Nkarta’s debut

...their offerings or priced above expectations. The most recent example of this trend came from Nkarta Inc....
...and selling more shares than expected, even after upsizing its proposal a day earlier (see “Nkarta’s...
Items per page:
1 - 10 of 28